Dingrui Nie

Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML.

Synergistic effects of BET inhibitors and ferroptosis inducers via targeted inhibition of the BRD4/c-Myc/NRF2 pathway in AML.

Journal: European journal of pharmacology

Published: February 20, 2025

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia.

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia.

Journal: International journal of nanomedicine

Published: July 08, 2024

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.

Journal: Molecular cancer

Published: June 20, 2024

CASP1 is a target for combination therapy in pancreatic cancer.

CASP1 is a target for combination therapy in pancreatic cancer.

Journal: European journal of pharmacology

Published: April 27, 2023

Overexpression of CASP1 triggers acute promyelocytic leukemia cell pyroptosis and differentiation.

Overexpression of CASP1 triggers acute promyelocytic leukemia cell pyroptosis and differentiation.

Journal: European journal of pharmacology

Published: January 08, 2023

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis.

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis.

Journal: Experimental hematology & oncology

Published: December 24, 2022

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.

Journal: Cell death & disease

Published: August 29, 2022

High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia.

High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia.

Journal: Cancer medicine

Published: March 25, 2022

Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis.

Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis.

Journal: Blood science (Baltimore, Md.)

Published: March 04, 2022

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.

Journal: Cell death & disease

Published: March 02, 2022

Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway.

Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway.

Journal: Journal of leukocyte biology

Published: November 26, 2021

MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway.

MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 18, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026